Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems

Journal of Pharmaceutical Sciences

Volumn 103, Issue 1, 2014, Pages 29-52

  Kraft, John C ^a   Freeling, Jennifer P ^a   Wang, Ziyao ^a   Ho, Rodney J Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

disposition; drug delivery systems; lipids; liposomes; micelle; nanoparticles; nanotechnology; pegylation; phospholipids

Indexed keywords

2B3 101; 7 ETHYL 10 HYDROXY CAMPTOTHECIN; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; BLINATUMOMAB; BORTEZOMIB; BUPIVACAINE; CONTRAST MEDIUM; CPX 1; CPX 351; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ENDOTAG 1; ESTRADIOL; FIRTECAN; HEPATITIS A VACCINE; INFLUENZA VACCINE; IRINOTECAN SUCROSOFATE; LIPID NANOPARTICLE; LIPOPLATIN; LIPOSOME; MACROGOL; MALARIA VACCINE; MBP 426; MITOPODOZIDE; MORPHINE SULFATE; NANOPARTICLE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PNU 91934; PROPOFOL; SGT 53; TECEMOTIDE; THERMODOX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VELIMOGENE ALIPLASMID; VERTEPORFIN; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ASPERGILLOSIS; BRAIN METASTASIS; BREAST CANCER; CARCINOMATOUS MENINGITIS; CIRCULATION TIME; CLINICAL STUDY; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SAFETY; DRUG TARGETING; ESOPHAGUS CANCER; GASTROINTESTINAL CARCINOMA; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; GLIOMA; HEPATITIS A; HUMAN; HYDRATION; IMMUNOGENICITY; INFLUENZA; KAPOSI SARCOMA; LEISHMANIASIS; LIPID BILAYER; LIPID COMPOSITION; LIPID MEMBRANE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALARIA; MALIGNANT LYMPHOMATOUS MENINGITIS; MALIGNANT MESOTHELIOMA; MENINGITIS; MENOPAUSAL SYNDROME; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MICELLE; MONONUCLEAR PHAGOCYTE; MULTIPLE MYELOMA; NANOMEDICINE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PARTICLE SIZE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; POSTOPERATIVE PAIN; REFRACTORY CHEST WALL BREAST CANCER; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STOMACH CANCER; SURFACE PROPERTY; TISSUE DISTRIBUTION;

DISPOSITION; DRUG DELIVERY SYSTEMS; LIPIDS; LIPOSOMES; MICELLE; NANOPARTICLES; NANOTECHNOLOGY; PEGYLATION; PHOSPHOLIPIDS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; NANOMEDICINE; NANOPARTICLES;

EID: 84890506078     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23773     Document Type: Review

References (212)

1. Saunders L, Thomas IL., 1958. Diffusion studies with lysolecithin. J Chem Soc 483-485.
2. Bangham AD, Horne RW., 1964. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 8: 660-668.
3. Torchilin VP., 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4 (2): 145-160.
4. Kinman L, Brodie SJ, Tsai CC, Bui T, Larsen K, Schmidt A, Anderson D, Morton WR, Hu SL, Ho RJ,. 2003. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: A proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr 34 (4): 387-397.
5. James JS,. 1995. DOXIL approved for KS. AIDS treatment news (no. 236): 6.
6. James JS,. 1995. DOXIL approved by FDA. AIDS patient care (no. 9): 306.
7. 2. Ann Oncol 11 (8): 1029-1033.
8. Northfelt DW,. 1994. Stealth liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposis sarcoma (AIDS-KS) lesions than to normal skin (abstract #5). Proc Am Soc Clin Oncol 13: 51.
9. NDA. 2004. Doxil: New drug application. Center for Drug Evaluation & Research-FDA.
10. Lian T, Ho RJ,. 2001. Trends and developments in liposome drug delivery systems. J Pharm Sci 90 (6): 667-680.
11. Ramishetti S, Huang L,. 2012. Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv 3 (12): 1429-1445.
12. Gregoriadis G,. 2007. Liposome technology. III ed., New York: Informa Healthcare. Vol. I-III.
13. Torchilin VP, Weissig V,. 2003. Liposomes: A practical approach. 2nd ed. Oxford; New York: Oxford University Press, p xxiii, 396.
14. Allen TM, Cullis PR,. 2012. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 65 (1): 36-48.
15. Mabrey S, Mateo PL, Sturtevant JM,. 1978. High-sensitivity scanning calorimetric study of mixtures of cholesterol with dimyristoyl- and dipalmitoylphosphatidylcholines. Biochemistry 17 (12): 2464-2468.
16. Angst MS, Drover DR,. 2006. Pharmacology of drugs formulated with DepoFoam: A sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet 45 (12): 1153-1176.
17. Katre NV,. 2004. Liposomes-based depot injection technologies. Am J Drug Deliv 2 (4): 213-227.
18. Cullis PR, de Kruijff B,. 1979. Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim Biophys Acta 559 (4): 399-420.
19. Edidin M,. 2003. Lipids on the frontier: A century of cell-membrane bilayers. Nat Rev Mol Cell Biol 4 (5): 414-418.
20. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A,. 1991. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066 (1): 29-36.
21. Lee RJ, Low PS,. 1995. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233 (2): 134-144.
22. Lee RJ, Low PS,. 1994. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269 (5): 3198-3204.
23. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D,. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51 (4): 691-743.
24. Plank C, Mechtler K, Szoka FC, Jr., Wagner E,. 1996. Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery. Hum Gene Ther 7 (12): 1437-1446.
25. He C, Hu Y, Yin L, Tang C, Yin C,. 2010. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31 (13): 3657-3666.
26. Chonn A, Cullis PR, Devine DV,. 1991. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 146 (12): 4234-4241.
27. Szebeni J, Bedocs P, Rozsnyay Z, Weiszhar Z, Urbanics R, Rosivall L, Cohen R, Garbuzenko O, Bathori G, Toth M, Bunger R, Barenholz Y,. 2012. Liposome-induced complement activation and related cardiopulmonary distress in pigs: Factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 8 (2): 176-184.
28. Moghimi SM, Hamad I, Andresen TL, Jorgensen K, Szebeni J,. 2006. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 20 (14): 2591-2593.
29. Sou K, Tsuchida E,. 2008. Electrostatic interactions and complement activation on the surface of phospholipid vesicle containing acidic lipids: Effect of the structure of acidic groups. Biochim Biophys Acta 1778 (4): 1035-1041.
30. Risbo J, Jorgensen K, Sperotto MM, Mouritsen OG,. 1997. Phase behavior and permeability properties of phospholipid bilayers containing a short-chain phospholipid permeability enhancer. Biochim Biophys Acta 1329 (1): 85-96.
31. McMullen TP, Lewis RN, McElhaney RN,. 1993. Differential scanning calorimetric study of the effect of cholesterol on the thermotropic phase behavior of a homologous series of linear saturated phosphatidylcholines. Biochemistry 32 (2): 516-522.
32. Huang Z, Szoka FC, Jr,. 2008. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J Am Chem Soc 130 (46): 15702-15712.
33. Jorgensen K, Ipsen JH, Mouritsen OG, Zuckermann MJ,. 1993. The effect of anaesthetics on the dynamic heterogeneity of lipid membranes. Chem Phys Lipids 65 (3): 205-216.
34. Krill SL, Lau KY, Plachy WZ, Rehfeld SJ,. 1998. Penetration of dimyristoylphosphatidylcholine monolayers and bilayers by model beta-blocker agents of varying lipophilicity. J Pharm Sci 87 (6): 751-756.
35. Sullivan SM, Huang L,. 1986. Enhanced delivery to target cells by heat-sensitive immunoliposomes. Proc Natl Acad Sci USA 83 (16): 6117-6121.
36. Yanez AM, Wallace M, Ho R, Shen D, Yaksh TL,. 1995. Touch-evoked agitation produced by spinally administered phospholipid emulsion and liposomes in rats. Structure-activity relation. Anesthesiology 82 (5): 1189-1198.
37. Beauchamp C, Daddona PE, Menapace DP,. 1984. Properties of a novel PEG derivative of calf adenosine deaminase. Adv Exp Med Biol 165 (Pt A): 47-52.
38. Zhao XB, Muthusamy N, Byrd JC, Lee RJ,. 2007. Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. J Pharm Sci 96 (9): 2424-2435.
39. Allen TM, Chonn A,. 1987. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223 (1): 42-46.
40. Maruyama K, Yuda T, Okamoto A, Kojima S, Suginaka A, Iwatsuru M,. 1992. Prolonged circulation time in vivo of large unilamelar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta 1128 (1): 44-49.
41. Woodle MC, Matthay KK, Newman MS, Hidayat JE, Collins LR, Redemann C, Martin FJ, Papahadjopoulos D,. 1992. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1105 (2): 193-200.
42. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D,. 1992. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52 (19): 5135-5143.
43. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW,. 1993. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 53 (16): 3765-3770.
44. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y,. 1994. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54 (4): 987-992.
45. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K,. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 65 (1-2): 271-284.
46. Metselaar JM, Bruin P, de Boer LW, de Vringer T, Snel C, Oussoren C, Wauben MH, Crommelin DJ, Storm G, Hennink WE,. 2003. A novel family of L -amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem 14 (6): 1156-1164.
47. Takeuchi H, Kojima H, Yamamoto H, Kawashima Y,. 2001. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release 75 (1-2): 83-91.
48. Torchilin VP, Levchenko TS, Whiteman KR, Yaroslavov AA, Tsatsakis AM, Rizos AK, Michailova EV, Shtilman MI,. 2001. Amphiphilic poly-N- vinylpyrrolidones: Synthesis, properties and liposome surface modification. Biomaterials 22 (22): 3035-3044.
49. Torchilin VP, Trubetskoy VS,. 1995. Which polymers can make nanoparticuate drug carriers long-circulating? Adv Drug Deliv Rev 16: 141-155.
50. Whiteman KR, Subr V, Ulbrich K, Torchilin VP,. 2001. Poly(Hpma)-coated liposomes demonstrate prolonged circulation in mice. J Liposome Res 11 (2-3): 153-164.
51. Woodle MC,. 1998. Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev 32 (1-2): 139-152.
52. Roberts MJ, Bentley MD, Harris JM,. 2002. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54 (4): 459-476.
53. Pasut G, Veronese FM,. 2007. Polymer-drug conjugation, recent achievements and general strategies. Progr Polym Sci 32: 933-961.
54. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P,. 2012. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin on Drug Deliv 9 (11): 1319-1323.
55. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H,. 2007. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 122 (3): 349-355.
56. Wang X, Ishida T, Kiwada H,. 2007. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 119 (2): 236-244.
57. Schellekens H, Hennink WE, Brinks V,. 2013. The immunogenicity of polyethylene glycol: Facts and fiction. Pharm Res 30 (7): 1729-1734.
58. Moghimi SM, Hunter AC, Murray JC,. 2001. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 53 (2): 283-318.
59. Bertrand N, Leroux JC,. 2012. The journey of a drug-carrier in the body: An anatomo-physiological perspective. J Control Release 161 (2): 152-163.
60. Choi CH, Zuckerman JE, Webster P, Davis ME,. 2011. Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A 108 (16): 6656-6661.
61. Sarin H,. 2010. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2: 14.
62. Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG,. 1990. Understanding the coronary circulation through studies at the microvascular level. Circulation 82 (1): 1-7.
63. Townsley MI, Parker JC, Longenecker GL, Perry ML, Pitt RM, Taylor AE,. 1988. Pulmonary embolism: Analysis of endothelial pore sizes in canine lung. Am J Physiol 255 (5 Pt 2): H1075-1083.
64. Wisse E, Jacobs F, Topal B, Frederik P, De Geest B,. 2008. The size of endothelial fenestrae in human liver sinusoids: Implications for hepatocyte-directed gene transfer. Gene Ther 15 (17): 1193-1199.
65. Luft FC, Aronoff GR, Evan AP, Connors BA, Blase DK, Gattone VH,. 1982. Effects of moxalactam and cefotaxime on rabbit renal tissue. Antimicrobial Agents Chemother 21 (5): 830-835.
66. Ogawa S, Ota Z, Shikata K, Hironaka K, Hayashi Y, Ota K, Kushiro M, Miyatake N, Kishimoto N, Makino H,. 1999. High-resolution ultrastructural comparison of renal glomerular and tubular basement membranes. Am J Nephrol 19 (6): 686-693.
67. Lahdenkari AT, Lounatmaa K, Patrakka J, Holmberg C, Wartiovaara J, Kestila M, Koskimies O, Jalanko H,. 2004. Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol 15 (10): 2611-2618.
68. Conner SD, Schmid SL,. 2003. Regulated portals of entry into the cell. Nature 422 (6927): 37-44.
69. Rejman J, Oberle V, Zuhorn IS, Hoekstra D,. 2004. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 377 (Pt 1): 159-169.
70. Hillaireau H, Couvreur P,. 2009. Nanocarriers' entry into the cell: Relevance to drug delivery. Cell Mol Life Sci 66 (17): 2873-2896.
71. Wang J, Byrne JD, Napier ME, DeSimone JM,. 2011. More effective nanomedicines through particle design. Small 7 (14): 1919-1931.
72. Venturoli D, Rippe B,. 2005. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: Effects of molecular size, shape, charge, and deformability. Am J Physiol 288 (4): F605-F613.
73. Beaumier PL, Hwang KJ,. 1983. Effects of liposome size on the degradation of bovine brain sphingomyelin/cholesterol liposomes in the mouse liver. Biochim Biophys Acta 731 (1): 23-30.
74. Proffitt RT, Williams LE, Presant CA, Tin GW, Uliana JA, Gamble RC, Baldeschwieler JD,. 1983. Tumor-imaging potential of liposomes loaded with In-111-NTA: Biodistribution in mice. J Nucl Med 24 (1): 45-51.
75. Gabizon AA, Barenholz Y, Bialer M,. 1993. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharm Res 10 (5): 703-708.
76. Wagner A, Vorauer-Uhl K,. 2011. Liposome technology for industrial purposes. J Drug Deliv 2011: 591325.
77. Barenholz Y, Amselem S,. 1993. Quality control assays in the development and clinical use of liposome-based formulations. In Liposome technology;, Gregoriadis G, Ed. 2nd ed. Boca Raton: CRC Press, pp 527-616.
78. Bangham AD, Standish MM, Watkins JC,. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13 (1): 238-252.
79. Asmal M, Whitney JB, Luedemann C, Carville A, Steen R, Letvin NL, Geiben-Lynn R,. 2012. In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes. PLoS One 7 (11): e48234.
80. Batzri S, Korn ED,. 1973. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta 298 (4): 1015-1019.
81. Tejera-Garcia R, Ranjan S, Zamotin V, Sood R, Kinnunen PK,. 2011. Making unilamellar liposomes using focused ultrasound. Langmuir 27 (16): 10088-10097.
82. Mayhew E, Lazo R, Vail WJ, King J, Green AM,. 1984. Characterization of liposomes prepared using a microemulsifier. Biochim Biophys Acta 775 (2): 169-174.
83. Barnadas-Rodriguez R, Sabes M,. 2001. Factors involved in the production of liposomes with a high-pressure homogenizer. Int J Pharm 213 (1-2): 175-186.
84. Dennison SM, Sutherland LL, Jaeger FH, Anasti KM, Parks R, Stewart S, Bowman C, Xia SM, Zhang R, Shen X, Scearce RM, Ofek G, Yang Y, Kwong PD, Santra S, Liao HX, Tomaras G, Letvin NL, Chen B, Alam SM, Haynes BF,. 2011. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One 6 (11): e27824.
85. Amselem S, Gabizon A, Barenholz Y,. 1993. A large-scale method for the preparation of sterile and nonpyrogenic liposomal formulations of defined size distributions for clinical use. In Liposome technology;, Gregoriadis G, Ed. Boca Raton: CRC Press, pp 501-525.
86. Rameez S, Bamba I, Palmer AF,. 2010. Large scale production of vesicles by hollow fiber extrusion: A novel method for generating polymersome encapsulated hemoglobin dispersions. Langmuir 26 (7): 5279-5285.
87. Szoka F, Jr., Papahadjopoulos D,. 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 75 (9): 4194-4198.
88. Maitani Y, Soeda H, Junping W, Takayama K,. 2001. Modified ethanol injection method for liposomes containing beta-sitosterol beta- D -glucoside. J Liposome Res 11 (1): 115-125.
89. Gentine P, Bourel-Bonnet L, Frisch B,. 2012. Modified and derived ethanol injection toward liposomes: Development of the process. J Liposome Res 23 (1): 11-19.
90. Jaafar-Maalej C, Charcosset C, Fessi H,. 2011. A new method for liposome preparation using a membrane contactor. J Liposome Res 21 (3): 213-220.
91. Wagner A, Platzgummer M, Kreismayr G, Quendler H, Stiegler G, Ferko B, Vecera G, Vorauer-Uhl K, Katinger H,. 2006. GMP production of liposomes-A new industrial approach. J Liposome Res 16 (3): 311-319.
92. Meure LA, Foster NR, Dehghani F,. 2008. Conventional and dense gas techniques for the production of liposomes: a review. AAPS Pharm Sci Tech 9 (3): 798-809.
93. Lasch J, Weissig V, Brandl M,. 2003. Preparation of liposomes. In Liposomes: A practical approach;, Torchilin V, Weissig V, Eds. Oxford/New York: Oxford University Press, pp 3-29.
94. Schwendener RA,. 1993. The preparation of large volumes of sterile liposomes for clinical applications. In, Gregoriadis G, editor Liposome Technology, 2 ed., Boca Raton: CRC Press. p 487-500.
95. Frederiksen L, Anton K, van Hoogevest P, Keller HR, Leuenberger H,. 1997. Preparation of liposomes encapsulating water-soluble compounds using supercritical carbon dioxide. J Pharm Sci 86 (8): 921-928.
96. Spilimbergo S, Bertucco A,. 2003. Non-thermal bacterial inactivation with dense CO(2). Biotechnol Bioeng 84 (6): 627-638.
97. Zhang J, Davis TA, Matthews MA, Drews MJ, LaBerge M,. 2006. Sterilization using high-pressure carbon dioxide. J Supercritical Fluids 38 (3): 354-372.
98. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE,. 2009. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61 (6): 428-437.
99. Kim HR, Andrieux K, Delomenie C, Chacun H, Appel M, Desmaele D, Taran F, Georgin D, Couvreur P, Taverna M,. 2007. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis 28 (13): 2252-2261.
100. Goppert TM, Muller RH,. 2005. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur J Pharm Biopharm 60 (3): 361-372.
101. Cedervall T, Lynch I, Foy M, Berggard T, Donnelly SC, Cagney G, Linse S, Dawson KA,. 2007. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl 46 (30): 5754-5756.
102. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, Dawson KA,. 2007. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci 134-135: 167-174.
103. Scherphof G, Roerdink F, Waite M, Parks J,. 1978. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta 542 (2): 296-307.
104. Tall AR, Small DM,. 1977. Solubilisation of phospholipid membranes by human plasma high density lipoproteins. Nature 265 (5590): 163-164.
105. Mendez AJ, He JL, Huang HS, Wen SR, Hsia SL,. 1988. Interaction of rabbit lipoproteins and red blood cells with liposomes of egg yolk phospholipids. Lipids 23 (10): 961-967.
106. Papahadjopoulos D, Moscarello M, Eylar EH, Isac T,. 1975. Effects of proteins on thermotropic phase transitions of phospholipid membranes. Biochim Biophys Acta 401 (3): 317-335.
107. Devine DV, Wong K, Serrano K, Chonn A, Cullis PR,. 1994. Liposome-complement interactions in rat serum: Implications for liposome survival studies. Biochim Biophys Acta 1191 (1): 43-51.
108. Yan X, Scherphof GL, Kamps JA,. 2005. Liposome opsonization. J Liposome Res 15 (1-2): 109-139.
109. Maeda H,. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41: 189-207.
110. Bui T, Faltynek C, Ho RJ,. 1994. Differential disposition of soluble and liposome-formulated human recombinant interleukin-7: Effects on blood lymphocyte population in guinea pigs. Pharm Res 11 (5): 633-641.
111. Patel HM,. 1988. Fate of liposomes in the lymphatics. In Liposomes as drug carriers;, Gregoriadis G, Ed. New York: John Wiley & Sons, p 51.
112. Oussoren C, Storm G,. 2001. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50 (1-2): 143-156.
113. Higuchi M, Fokin A, Masters TN, Robicsek F, Schmid-Schonbein GW,. 1999. Transport of colloidal particles in lymphatics and vasculature after subcutaneous injection. J Appl Physiol 86 (4): 1381-1387.
114. Ikomi F, Hanna GK, Schmid-Schonbein GW,. 1999. Size- and surface-dependent uptake of colloid particles into the lymphatic system. Lymphology 32 (3): 90-102.
115. Oussoren C, Velinova M, Scherphof G, van der Want JJ, van Rooijen N, Storm G,. 1998. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. IV. Fate of liposomes in regional lymph nodes. Biochim Biophys Acta 1370 (2): 259-272.
116. Oussoren C, Zuidema J, Crommelin DJ, Storm G,. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1328 (2): 261-272.
117. Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S,. 2000. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J Exp Med 192 (10): 1425-1440.
118. Fidler IJ, Sone S, Fogler WE, Barnes ZL,. 1981. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78 (3): 1680-1684.
119. Li S, Goins B, Hrycushko BA, Phillips WT, Bao A,. 2012. Feasibility of eradication of breast cancer cells remaining in postlumpectomy cavity and draining lymph nodes following intracavitary injection of radioactive immunoliposomes. Mol Pharm 9 (9): 2513-2522.
120. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD,. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278 (5341): 1291-1295.
121. Wong JK, Gunthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, Kwok S, Emini E, Richman DD,. 1997. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 94 (23): 12574-12579.
122. Ruiz L, van Lunzen J, Arno A, Stellbrink HJ, Schneider C, Rull M, Castella E, Ojanguren I, Richman DD, Clotet B, Tenner-Racz K, Racz P,. 1999. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 13 (1): F1-F8.
123. Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP,. 1999. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 189 (10): 1545-1554.
124. Kinman L, Bui T, Larsen K, Tsai CC, Anderson D, Morton WR, Hu SL, Ho RJ,. 2006. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr 42 (2): 155-161.
125. Matsumura Y, Maeda H,. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46 (12 Pt 1): 6387-6392.
126. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF,. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (4587): 983-985.
127. Northfelt DW, Kaplan L, Russell J,. 1995. Pharmacokinetics and tumor localization of DOX-SL (Stealth liposomal doxorubicin) by comparison with Adriamycin in patients with AIDS and Kaposi's sarcoma. In Stealth liposomes;, Lasic DD, Martin FJ, Eds. Boca Raton, Florida: CRC Press, pp 257-266.
128. Forssen EA, Coulter DM, Proffitt RT,. 1992. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52 (12): 3255-3261.
129. Adiseshaiah PP, Hall JB, McNeil SE,. 2009. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev 2 (1): 99-112.
130. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG,. 2012. Treating metastatic cancer with nanotechnology. Nat Rev 12 (1): 39-50.
131. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC,. 2013. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73 (8): 2412-2417.
132. Strebhardt K, Ullrich A,. 2008. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev 8 (6): 473-480.
133. Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC,. 2010. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107 (42): 17939-17944.
134. Heath TD, Fraley RT, Papahdjopoulos D,. 1980. Antibody targeting of liposomes: Cell specificity obtained by conjugation of F(ab')2 to vesicle surface. Science 210 (4469): 539-541.
135. Leserman LD, Barbet J, Kourilsky F, Weinstein JN,. 1980. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288 (5791): 602-604.
136. Endsley AN, Ho RJ,. 2012. Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles. J Acquir Immune Defici Syndromes 61 (4): 417-424.
137. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (7407): 330-337.
138. 2012. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 (7417): 519-525.
139. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490 (7418): 61-70.
140. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA,. 2013. Integrated genomic characterization of endometrial carcinoma. Nature 497 (7447): 67-73.
141. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med 368 (22): 2059-2074.
142. Rajendran L, Knolker HJ, Simons K,. 2010. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 9 (1): 29-42.
143. Mayor S, Rothberg KG, Maxfield FR,. 1994. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science 264 (5167): 1948-1951.
144. Varma R, Mayor S,. 1998. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature 394 (6695): 798-801.
145. Schnitzer JE,. 2001. Caveolae: From basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. Adv Drug Deliv Rev 49 (3): 265-280.
146. Lv Q, Li LM, Han M, Tang XJ, Yao JN, Ying XY, Li FZ, Gao JQ,. 2013. Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome. Int J Pharm 444 (1-2): 1-9.
147. Miller K, Shipman M, Trowbridge IS, Hopkins CR,. 1991. Transferrin receptors promote the formation of clathrin lattices. Cell 65 (4): 621-632.
148. Altschuler Y, Kinlough CL, Poland PA, Bruns JB, Apodaca G, Weisz OA, Hughey RP,. 2000. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell 11 (3): 819-831.
149. Wang CY, Huang L,. 1987. Plasmid DNA adsorbed to pH-sensitive liposomes efficiently transforms the target cells. Biochem Biophys Res Commun 147 (3): 980-985.
150. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC,. 2004. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 8 (4): 335-353.
151. Ho RJ, Chien JY,. 2013. Trends in translational medicine and drug targeting and delivery: New insights on an old concept-Targeted drug delivery with antibody-drug conjugates for cancers. J Pharm Sci [Epub ahead of print].
152. Alexis F, Pridgen EM, Langer R, Farokhzad OC,. 2010. Nanoparticle technologies for cancer therapy. Handbook Exp Pharm (197): 55-86.
153. Torchilin VP,. 2010. Passive and active drug targeting: Drug delivery to tumors as an example. Handbook Exp Pharma (197): 3-53.
154. Jiang W, Kim BY, Rutka JT, Chan WC,. 2008. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3 (3): 145-150.
155. Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P,. 2010. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci USA 107 (33): 14541-14546.
156. Mann AP, Bhavane RC, Somasunderam A, Liz Montalvo-Ortiz B, Ghaghada KB, Volk D, Nieves-Alicea R, Suh KS, Ferrari M, Annapragada A, Gorenstein DG, Tanaka T,. 2011. Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget 2 (4): 298-304.
157. Willis MC, Collins BD, Zhang T, Green LS, Sebesta DP, Bell C, Kellogg E, Gill SC, Magallanez A, Knauer S, Bendele RA, Gill PS, Janjic N,. 1998. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem 9 (5): 573-582.
158. Cao Z, Tong R, Mishra A, Xu W, Wong GC, Cheng J, Lu Y,. 2009. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl 48 (35): 6494-6498.
159. Li SD, Chen YC, Hackett MJ, Huang L,. 2008. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 16 (1): 163-169.
160. Nakagawa O, Ming X, Huang L, Juliano RL,. 2010. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc 132 (26): 8848-8849.
161. Reddy BS, Banerjee R,. 2005. 17Beta-estradiol-associated stealth-liposomal delivery of anticancer gene to breast cancer cells. Angew Chem Int Ed Engl 44 (41): 6723-6727.
162. Sapsford KE, Algar WR, Berti L, Gemmill KB, Casey BJ, Oh E, Stewart MH, Medintz IL,. 2013. Functionalizing nanoparticles with biological molecules: Developing chemistries that facilitate nanotechnology. Chem Rev 113 (3): 1904-2074.
163. Gray BP, Li S, Brown KC,. 2013. From phage display to nanoparticle delivery: Functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug Chem 24 (1): 85-96.
164. Humphries HE, Williams JN, Blackstone R, Jolley KA, Yuen HM, Christodoulides M, Heckels JE,. 2006. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. Vaccine 24 (1): 36-44.
165. Ravikumar M, Modery CL, Wong TL, Gupta AS,. 2012. Peptide-decorated liposomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro. Biomacromolecules 13 (5): 1495-1502.
166. Portell CA, Advani AS,. 2013. Novel targeted therapies in acute lymphoblastic leukemia. Leuk Lymphoma.
167. Portell CA, Wenzell CM, Advani AS,. 2013. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 5 (Suppl 1): 5-11.
168. Xia W, Low PS,. 2010. Folate-targeted therapies for cancer. J Med Chem 53 (19): 6811-6824.
169. Perche F, Torchilin VP,. 2013. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv 2013: 705265.
170. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP,. 2006. " SMART" drug delivery systems: Double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 17 (4): 943-949.
171. Zhu L, Kate P, Torchilin VP,. 2012. Matrix metalloprotease 2-responsive
172. Xiang B, Dong DW, Shi NQ, Gao W, Yang ZZ, Cui Y, Cao DY, Qi XR,. 2013. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials 34 (28): 6976-6991.
173. Oude Blenke E, Mastrobattista E, Schiffelers RM,. 2013. Strategies for triggered drug release from tumor targeted liposomes. Expert Opin Drug Deliv.
174. Yudina A, de Smet M, Lepetit-Coiffe M, Langereis S, Van Ruijssevelt L, Smirnov P, Bouchaud V, Voisin P, Grull H, Moonen CT,. 2011. Ultrasound-mediated intracellular drug delivery using microbubbles and temperature-sensitive liposomes. J Control Release 155 (3): 442-448.
175. Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simoes S, Moreira JN,. 2012. Lipid-based nanoparticles for siRNA delivery in cancer therapy: Paradigms and challenges. Acc Chem Res 45 (7): 1163-1171.
176. Janib SM, Moses AS, MacKay JA,. 2010. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 62 (11): 1052-1063.
177. Bui T, Stevenson J, Hoekman J, Zhang S, Maravilla K, Ho RJ,. 2010. Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging. PLoS One 5 (9).
178. Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA,. 2009. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27 (27): 3643-3649.
179. Bhowmick S, Mazumdar T, Sinha R, Ali N,. 2010. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. J Control Release 141 (2): 199-207.
180. Badiee A, Jaafari MR, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F,. 2009. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition. Colloids Surf 74 (1): 37-44.
181. Davis D, Gregoriadis G,. 1987. Liposomes as adjuvants with immunopurified tetanus toxoid: Influence of liposomal characteristics. Immunology 61 (2): 229-234.
182. Gregoriadis G, Davis D, Davies A,. 1987. Liposomes as immunological adjuvants: Antigen incorporation studies. Vaccine 5 (2): 145-151.
183. Alving CR, Rao M,. 2008. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 26 (24): 3036-3045.
184. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, Garcia-Sastre A, Compans R, Pulendran B,. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470 (7335): 543-547.
185. Shahum E, Therien HM,. 1994. Correlation between in vitro and in vivo behaviour of liposomal antigens. Vaccine 12 (12): 1125-1131.
186. Therien HM, Lair D, Shahum E,. 1990. Liposomal vaccine: Influence of antigen association on the kinetics of the humoral response. Vaccine 8 (6): 558-562.
187. Guan HH, Budzynski W, Koganty RR, Krantz MJ, Reddish MA, Rogers JA, Longenecker BM, Samuel J,. 1998. Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 9 (4): 451-458.
188. + T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine 23 (1): 58-68.
189. Nair S, Zhou F, Reddy R, Huang L, Rouse BT,. 1992. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 175 (2): 609-612.
190. Perrie Y, Frederik PM, Gregoriadis G,. 2001. Liposome-mediated DNA vaccination: The effect of vesicle composition. Vaccine 19 (23-24): 3301-3310.
191. Chen WC, Huang L,. 2005. Non-viral vector as vaccine carrier. Adv Genet 54: 315-337.
192. Sonawane ND, Szoka FC, Jr., Verkman AS,. 2003. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 278 (45): 44826-44831.
193. Legendre JY, Szoka Jr FC,. 1992. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: Comparison with cationic liposomes. Pharm Res 9 (10): 1235-1242.
194. Nel AE, Madler L, Velegol D, Xia T, Hoek EM, Somasundaran P, Klaessig F, Castranova V, Thompson M,. 2009. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8 (7): 543-557.
195. Sullivan SM, Doukas J, Hartikka J, Smith L, Rolland A,. 2010. Vaxfectin: A versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv 7 (12): 1433-1446.
196. Chowdhery R, Gonzalez R,. 2011. Immunologic therapy targeting metastatic melanoma: Allovectin-7. Immunotherapy 3 (1): 17-21.
197. Van Driessche A, Ponsaerts P, Van Bockstaele DR, Van Tendeloo VF, Berneman ZN,. 2005. Messenger RNA electroporation: An efficient tool in immunotherapy and stem cell research. Folia Histochem Cytobiol 43 (4): 213-216.
198. Wang Y, Su HH, Yang Y, Hu Y, Zhang L, Blancafort P, Huang L,. 2013. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther 21 (2): 358-367.
199. Leung AK, Hafez IM, Baoukina S, Belliveau NM, Zhigaltsev IV, Afshinmanesh E, Tieleman DP, Hansen CL, Hope MJ, Cullis PR,. 2012. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J Phys Chem C 116 (34): 18440-18450.
200. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ,. 2010. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28 (2): 172-176.
201. Kokkona M, Kallinteri P, Fatouros D, Antimisiaris SG,. 2000. Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: Effect of lipid composition. Eur J Pharm Sci 9 (3): 245-252.
202. Moutardier V, Tosini F, Vlieghe P, Cara L, Delpero JR, Clerc T,. 2003. Colloidal anticancer drugs bioavailabilities in oral administration models. Int J Pharm 260 (1): 23-38.
203. Taira MC, Chiaramoni NS, Pecuch KM, Alonso-Romanowski S,. 2004. Stability of liposomal formulations in physiological conditions for oral drug delivery. Drug Deliv 11 (2): 123-128.
204. Parmentier J, Thomas N, Mullertz A, Fricker G, Rades T,. 2012. Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis. Int J Pharm 437 (1-2): 253-263.
205. Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP,. 2006. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23 (6): 1243-1250.
206. Yang S, Gursoy RN, Lambert G, Benita S,. 2004. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21 (2): 261-270.
207. Porter CJ, Trevaskis NL, Charman WN,. 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6 (3): 231-248.
208. Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Quinkert RO, Martin F, Muller-Goymann C,. 2010. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 27 (8): 1469-1486.
209. Minato S, Iwanaga K, Kakemi M, Yamashita S, Oku N,. 2003. Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: Effect of lipid dose on systemic and mucosal immunity. J Control Release 89 (2): 189-197.
210. Imanaka H, Koide H, Shimizu K, Asai T, Kinouchi Shimizu N, Ishikado A, Makino T, Oku N,. 2008. Chemoprevention of tumor metastasis by liposomal beta-sitosterol intake. Biol Pharm Bull 31 (3): 400-404.
211. Rogers JA, Anderson KE,. 1998. The potential of liposomes in oral drug delivery. Crit Rev Ther Drug Carrier Syst 15 (5): 421-480.
212. White M, Pelletier GB, Tan A, Jesina C, Carrier M,. 1997. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. J Heart Lung Transplant 16 (8): 787-794.